Market Overview

ARIAD Presents Positive Phase 1/2 Trial Data on AP26113 in Patients with Non-Small Cell Lung Cancer at ECC 2013

ARIAD
Pharmaceuticals (NASDAQ: ARIA) today announced updated
clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113,
in patients with advanced non-small cell lung cancer (NSCLC) from an
ongoing Phase 1/2 trial. These study results show robust anti-tumor
activity of AP26113 in patients with TKI-naïve and crizotinib-resistant
anaplastic lymphoma kinase positive (ALK+) NSCLC, including in patients
with brain metastases after crizotinib treatment. Crizotinib is the
currently available first-generation ALK inhibitor.

The updated Phase 1/2 results are being presented this morning at the
European Cancer Congress (the 38th ESMO, 32nd ESTRO, 17th ECCO
conference) being held in Amsterdam.

Phase 1/2

See full press release

Posted-In: News Guidance Management Global

 

Most Popular

Related Articles (ARIA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters